PBLS (47) ACAD (49) IRON (54) AMLX (39) ⌘ Pro Terminal →

Viking Therapeutics Inc. (VKTX) — RQD Stock Rating Cockpit

$27.28 +1.56% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $27.30

Viking Therapeutics Inc. (VKTX) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $3.48B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on VKTX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is VKTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Viking Therapeutics Inc. (NASDAQ: VKTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $27.28 (+1.56% 1D, market cap $3.48B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, VKTX ranks #400 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does VKTX compare to PBLS and ACAD in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VKTX carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PBLS (Parabilis Medicines Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $3.45B) and ACAD (ACADIA Pharmaceuticals Inc.) posts a D grade (49/100 RQD, P/E 9.1x, ROIC 7.9%, cap $3.55B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while ACAD leads on capital efficiency (7.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for VKTX?

▼

Per VKTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001607678), Viking Therapeutics Inc. generated $0 in revenue, -$359.6M in net income, and -$278.7M in free cash flow against $715.7M in total assets and $34.5M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $27.30 (+0.09%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-6.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VKTX)Realized 20D OHLCV Swing Band: ±12%

Deterministic 5-Pillar Attribution (43/100 Composite)

🔍 WHY VKTX SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (37% of score)

Altman Z-Score 24.02 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (19% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 0% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$25.47+3.6% Next Q

Q2 (-2Q)

Grade E$26.38-3.9% Next Q

Q3 (-1Q)

Grade D$25.36+7.6% Next Q

Current

Grade D-$27.28-6.7% Hist 90D α

Trajectory: E (35) → D- (43)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a VKTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While VKTX currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Clean SEC annual filing review with no major hidden accounting time-bombs.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($30.11) and Max Pain ($28.64) forces dealer call-delta covering toward $45.31.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VKTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “VKTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 43%NO 57%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

48.330 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

24.02>3.0 Fortress Safe

PIOTROSKI F-SCORESOLID CORE (5–6)

5 / 99-Pt Accounting

52-WEEK LASER RANGE18% OF RANGE

L: $24$27.28H: $43

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 11 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: C-RQD 24 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on VKTX

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (40)

-35.0% ROIC with 42.0% gross margin and -8.25% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (80)

Altman-Z 24.02 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (32)

11/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like VKTX

✓Clean SEC annual filing review with no major hidden accounting time-bombs.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VKTX)

✓Walkthrough of VKTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

VKTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -14.11%📐 HORIZONTAL RANGE

2026-11-03O $26.86H $27.28L $26.86C $27.28VOL 5.14M

RES: $43.27SUP: $22.82SMA50: $30.11SMA200: $32.31

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VKTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VKTX Butterfly Map → + Track VKTX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

27.0%/yr Implied 5Y Growth

vs. +15.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on VKTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VKTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for VKTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VKTX)

Health Care Rank #400 of 1016 ⚔️ PBLS vs VKTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VKTX vs. PBLS, ACAD, IRON, AMLX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Viking Therapeutics Inc. (VKTX) ranks #400 by composite RQD confidence (43/100, grade D-) and #194 by equity capitalization ($3.48B). Within this direct 5-issuer industry benchmark cohort, ACAD leads on earnings valuation at 9.1x trailing P/E, while ACAD leads on capital efficiency and profitability with 7.9% ROIC and 91.7% gross margin. IRON currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with VKTX at 43/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
VKTX ACTIVE Viking Therapeutics Inc.	D-	43/100	—	—	-35.0%	+1.56%	$3.48B	Benchmark Subject
PBLS Parabilis Medicines Inc.	D	47/100	—	—	—	-1.32%	$3.45B	/pbls-vs-vktx →
ACAD ACADIA Pharmaceuticals Inc.	D	49/100	9.1x	91.7%	7.9%	-0.82%	$3.55B	/acad-vs-vktx →
IRON Disc Medicine Inc.	D+	54/100	—	—	-27.5%	-2.41%	$3.59B	/iron-vs-vktx →
AMLX Amylyx Pharmaceuticals Inc.	D-	39/100	—	—	-35.0%	+0.63%	$3.62B	/amlx-vs-vktx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001607678

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Viking Therapeutics Inc. (VKTX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$359.6M, operating cash flow of -$278.7M, and free cash flow of -$278.7M (-217.4% YoY). On the balance sheet, VKTX closed FY2025 with $715.7M in total assets against $34.5M in total debt (Altman Z-Score: 24.02, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$359.6M	-$278.7M	-$278.7M	$715.7M	$34.5M
FY2024 (FY)	2024-12-31	$0	-$110.0M	-$87.8M	-$87.8M	$908.3M	$12.6M
FY2023 (FY)	2023-12-31	$0	-$85.9M	-$73.4M	-$73.4M	$1.86B	$434.5M

3. VKTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VKTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does VKTX compare to PBLS and ACAD in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for VKTX?

Where is VKTX trading relative to its 50-day, 200-day, and 52-week technical levels?

VKTX last traded at $27.28 (+1.56% on volume of 5,143,539 shares), positioning the stock -9.40% below its 50-day simple moving average ($30.11) and -15.57% below its 200-day simple moving average ($32.31). Across its 52-week range of $23.82 to $43.15, VKTX sits at the 17.9% percentile with a 14-day RSI of 48.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.0% ($24.01 to $30.55).

VKTX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell VKTX stock right now?

Viking Therapeutics Inc. (VKTX) currently earns a Roarable Rating of D- (Sell — SELL) with 43/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is VKTX's 12-month price target and RQD AI Jury consensus?

VKTX's 12-month base price target is $25.44 (range $19.84 to $45.31), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: VKTX RQD Cockpit VKTX 12M Forecast VKTX Earnings & Move VKTX Dividends & DRIP VKTX Insiders & 13F VKTX Whale Options VKTX Profit Sankey VKTX News & Why

ROARABLE RATING BRIEF • RQD 43/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

VKTX — Viking Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:23:29Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating is 44, grade D, labeled "Roarable Sell — Underperform / Distribution Warning" (per the Roarable RQD rating). Across its five pillars, the rating shows:

Fundamental Cash Engine: 8 / 20 — ROIC of -35% and FCF yield of -8.25% (per the Roarable RQD rating and market data). Negative returns on capital and negative free cash flow yield indicate the business is currently consuming rather than generating cash relative to its valuation.
Whale 13F Flow: 7 / 20 — the rating reflects institutional accumulation and options positioning, but no 13F holder detail is provided in the holders section (per the Roarable RQD rating; holders: Not available in source data).
Insider Conviction: 5 / 20 — the lowest pillar, reflecting SEC Form 4 and Congressional PTR cluster flow (per the Roarable RQD rating). Weak insider conviction is a caution signal, though the underlying transactions are not itemized in the source data.
Macro Regime Fit: 8 / 20 — beta of 0.91 and sector sensitivity (per the Roarable RQD rating and market data). A beta below 1.0 suggests the stock has moved less than the market on average, but the low score signals poor alignment with the prevailing regime.
Forensic Balance Sheet: 16 / 20 — the strongest pillar, citing Altman Z 24.02, Piotroski F 5/9, and Debt/Equity 0.05 (per the Roarable RQD rating). The balance sheet is the rating's primary support, indicating solvency is not the immediate concern.

Investor implications: The upside case rests on the balance sheet's durability, which gives the company runway, and on the wide gap between the current price and the cited analyst-style upside narrative in the news wire. The valuation tradeoff is that forward P/E of 35 is present while EPS TTM is -2.86 and returns on capital are deeply negative, so the stock is priced on expectations the trailing data does not yet support. The rating's overall verdict is a distribution warning, meaning weakness in cash generation and insider conviction outweighs balance sheet strength.

Business

Viking Therapeutics Inc. (VKTX) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry (per the company profile). Its market capitalization is $3.4B (per the company profile). The source data does not specify its products, customers, or revenue model. Reported revenue is $0.0M in each period shown (per the SEC financials).

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-393.3M	$-359.6M	N/A	$-278.7M	$165.8M	$34.5M
FY 2024	$0.0M	$-150.9M	$-110.0M	N/A	$-87.8M	$26.7M	$12.6M
FY 2023	$0.0M	$-100.8M	$-85.9M	N/A	$-73.4M	N/A	$434.5M

Per the SEC financials, the company reported losses in each period, with operating losses widening from $-100.8M in FY 2023 to $-393.3M in FY 2025. Gross, operating, and net margins are each 0% per the market data, and ROIC is -35%. The Altman Z-Score is 24.02 and the Piotroski F-Score is 5/9 (per the Roarable RQD rating). Debt/Equity is 0.05 (per the Roarable RQD rating), while cash rose to $165.8M in FY 2025 against debt of $34.5M (per the SEC financials).

Recent Catalysts & News Wire Analysis

RISK WATCH (RED): A Yahoo Finance headline reports the stock dropped and asks what is driving attention (per the news wire).
CATALYST (GREEN): A Motley Fool piece cites an Oppenheimer price target of $120 on the stock (per the news wire).
CATALYST (GREEN): A BioSpace piece covers significant stock movers of September, with Viking highlighted as soaring (per the news wire).
MARKET WIRE (YELLOW): Investing.com and Yahoo Finance quote and history pages (per the news wire).
MARKET WIRE (YELLOW): A Motley Fool long-horizon piece on a $1,000 investment (per the news wire).

Proprietary signals: Not available in source data (per the Butterfly Supply-Chain Graph, proprietary signals list is empty).

Open Questions

What drove the 5.92% price change and the "dropped" move flagged in the risk-watch headline?
What are the company's pipeline, products, and revenue timing, given revenue is reported as $0.0M across all periods?
What is the composition and timing of insider Form 4 and Congressional PTR transactions behind the 5/20 insider pillar?
Who are the principal 13F institutional holders behind the 7/20 whale-flow pillar?
What is the basis for the cited $120 price target, and what is the consensus analyst rating?

VKTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Viking Therapeutics Inc. (VKTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to VKTX Debate Forum (3) ↓

🔴 RISK WATCH Yahoo Finance • 18h ago

Viking Therapeutics (VKTX) Stock Dropped, So What Is Driving Attention Now?

Yahoo Finance report covering Viking Therapeutics Inc. (VKTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST The Motley Fool • 21h ago

Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call.

The Motley Fool report covering Viking Therapeutics Inc. (VKTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST BioSpace • 1d ago

Significant stock movers of September: Viking soars, Longeveron slides

BioSpace report covering Viking Therapeutics Inc. (VKTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 1d ago

Viking Therapeutics Inc Stock Price Today | NASDAQ: VKTX Live

Investing.com report covering Viking Therapeutics Inc. (VKTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Viking Therapeutics, Inc. (VKTX) Stock Price, News, Quote & History

Yahoo Finance report covering Viking Therapeutics Inc. (VKTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Motley Fool • 1d ago

Prediction: $1,000 Invested in Viking Therapeutics Today Will Be Worth This Much in 5 Years

The Motley Fool report covering Viking Therapeutics Inc. (VKTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Viking Therapeutics (VKTX) Stock Looks Overvalued Next To Its Book Value

Yahoo Finance report covering Viking Therapeutics Inc. (VKTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Motley Fool • 1d ago

Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?

The Motley Fool report covering Viking Therapeutics Inc. (VKTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

VKTX Bull vs. Bear Conversation Board — What's Your Call at $27.28?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VKTX 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $23.64 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is VKTX (D • RQD 44/100) a Buy at $26.86?

Welcome to the VKTX (Viking Therapeutics Inc.) Roar Pit. Current RQD Composite is 44/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $21.49 (-20.0%)

Spot @ $26.86

Pump the brakes on VKTX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on VKTX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Viking Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $33.04 (+23.0%)

Spot @ $26.86

VKTX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on VKTX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $26.86 (52-wk range $23.82 - $43.15), any beat on forward guidance forces shorts and underweight funds to chase.